The impact of obesity on neurodegenerative diseases.
Abstract
Neurodegenerative diseases are a growing health concern. The increasing incidences of these disorders have a great impact on the patients' quality of life. Although the mechanisms of neurodegenerative diseases are still far from being clarified, several studies look for new discoveries about their pathophysiology and prevention. Furthermore, evidence has shown a strong correlation between obesity and the development of Alzheimer's disease (AD) and Parkinson's disease (PD). Metabolic changes caused by overweight are related to damage to the central nervous system (CNS), which can lead to neural death, either by apoptosis or cell necrosis, as well as alter the synaptic plasticity of the neuron. This review aims to show the association between neurodegenerative diseases, focusing on AD and PD, and metabolic alterations.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Metabolic diseases such as obesity increase the risk of developing neurodegenerative disease such as Alzheimer's disease.
“Additionally, it has been reported that metabolic diseases, such as obesity, increase the risk of developing neurodegenerative disease such as Alzheimer’s disease (AD) (Mazon et al., 2017; Zhuang et al., 2021).”
From Deletion of the Alzheimer’s disease risk gene Abi3 locus results in obesity and systemic metabolic disruption in mice (2022) · cites this paper as Mazon et al., 2017
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · see citing works
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · see citing works
Inflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212 · see citing works
Ogden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561 · see citing works
Adipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050 · see citing works
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688 · see citing works
Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Agostinho, P., A. Cunha, R., & Oliveira, C. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793176572 · Cited by 685 · see citing works
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · see citing works
Leptin in Human Physiology and Pathophysiology
Mantzoros, C. S., Magkos, F., Brinkoetter, M., Sienkiewicz, E., Dardeno, T. A., Kim, S.-Y., Hamnvik, O.-P. R., & Koniaris, A. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2011 · Cited by 593 · see citing works
Nguyen, D. M., & El-Serag, H. B. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.014 · Cited by 531 · see citing works
The role of the LRRK2 gene in Parkinsonism
Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249 · see citing works
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174 · see citing works
Hypothalamic innate immune reaction in obesity
Kälin, S., Heppner, F. L., Bechmann, I., Prinz, M., Tschöp, M. H., & Yi, C.-X. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.48 · Cited by 167 · see citing works
Hypothalamic inflammation and energy homeostasis: Resolving the paradox
Thaler, J. P., Choi, S. J., Schwartz, M. W., & Wisse, B. E. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.10.002 · Cited by 144 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Safaei, M., Sundararajan, E. A., Driss, M., Boulila, W., & Shapi'i, A. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104754 · Cited by 720 · see citing works
Interplay between the gut-brain axis, obesity and cognitive function
Agustí, A., García-Pardo, M. P., López-Almela, I., Campillo, I., Maes, M., Romaní-Pérez, M., & Sanz, Y. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00155 · Cited by 294 · see citing works
Flavonoids as Antiobesity Agents: A Review
Rufino, A. T., Costa, V. M., Carvalho, F., & Fernandes, E. (2021) · Medicinal Research Reviews · doi:10.1002/med.21740 · Cited by 174 · see citing works
Liu, X., Shen, L., Wan, M., Xie, H., & Wang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02428-1 · Cited by 33 · see citing works
Li, X., Zhao, J., Li, Z., Zhang, L., & Huo, Z. (2020) · Neural Plasticity · doi:10.1155/2020/8850653 · Cited by 35 · see citing works
Smith, D. C., Karahan, H., Wijeratne, H. R. S., Al-Amin, M., McCord, B., Moon, Y., & Kim, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1035572 · Cited by 8 · see citing works
“Additionally, it has been reported that metabolic diseases, such as obesity, increase the risk of developing neurodegenerative disease such as Alzheimer’s disease (AD) (Mazon et al., 2017; Zhuang et al., 2021).”
BackgroundHatton‐Jones, K. M., du Toit, E. F., & Cox, A. J. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14300 · Cited by 5 · see citing works
- Authors
- Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T.
- Affiliations
- Universidade Federal do Paraná (BR)
- Universidade do Sul de Santa Catarina (BR)
- Corresponding author
- Ferreira, Gabriela Kozuchovski
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 182
- Pages
- 22-28
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2621103340
- Cited by
- 185
- References
- 14
- Citations by year
- 2026: 6 · 2025: 31 · 2024: 23 · 2023: 29 · 2022: 17 · 2021: 26 · 2020: 29 · 2019: 13 · 2018: 6 · 2017: 4
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Life Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- obesity, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, metabolic changes, central nervous system injury, apoptosis, necrosis, synaptic plasticity, pathophysiology, disease prevention
- MeSH terms
- Alzheimer Disease, Animals, Humans, Obesity, Parkinson Disease, Quality of Life, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
